Current insights and molecular docking studies of HIV-1 reverse transcriptase inhibitors

Simple item page
dc.contributor.authorSingh, Ankit Kumar
dc.contributor.authorKumar, Adarsh
dc.contributor.authorArora, Sahil
dc.contributor.authorKumar, Raj
dc.contributor.authorVerma, Amita
dc.contributor.authorKhalilullah, Habibullah
dc.contributor.authorJaremko, Mariusz
dc.contributor.authorEmwas, Abdul-Hamid
dc.contributor.authorKumar, Pradeep
dc.date.accessioned2024-01-21T10:38:38Z
dc.date.accessioned2024-08-13T12:05:35Z
dc.date.available2024-01-21T10:38:38Z
dc.date.available2024-08-13T12:05:35Z
dc.date.issued2023-10-12T00:00:00
dc.description.abstractHuman immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome (AIDS), a lethal disease that is prevalent worldwide. According to the Joint United Nations Programme on HIV/AIDS (UNAIDS) data, 38.4 million people worldwide were living with HIV in 2021. Viral reverse transcriptase (RT) is an excellent target for drug intervention. Nucleoside reverse transcriptase inhibitors (NRTIs) were the first class of approved antiretroviral drugs. Later, a new type of non-nucleoside reverse transcriptase inhibitors (NNRTIs) were approved as anti-HIV drugs. Zidovudine, didanosine, and stavudine are FDA-approved NRTIs, while nevirapine, efavirenz, and delavirdine are FDA-approved NNRTIs. Several agents are in clinical trials, including apricitabine, racivir, elvucitabine, doravirine, dapivirine, and elsulfavirine. This review addresses HIV-1 structure, replication cycle, reverse transcription, and HIV drug targets. This study focuses on NRTIs and NNRTIs, their binding sites, mechanisms of action, FDA-approved drugs and drugs in clinical trials, their resistance and adverse effects, their molecular docking studies, and highly active antiretroviral therapy (HAART). � 2023 John Wiley & Sons Ltd.en_US
dc.identifier.doi10.1111/cbdd.14372
dc.identifier.issn17470277
dc.identifier.urihttp://10.2.3.109/handle/32116/3622
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/10.1111/cbdd.14372
dc.language.isoen_USen_US
dc.publisherJohn Wiley and Sons Incen_US
dc.subjectAIDSen_US
dc.subjectHAARTen_US
dc.subjectHIVen_US
dc.subjectNNRTIen_US
dc.subjectNRTIen_US
dc.subjectRTen_US
dc.titleCurrent insights and molecular docking studies of HIV-1 reverse transcriptase inhibitorsen_US
dc.title.journalChemical Biology and Drug Designen_US
dc.typeReviewen_US
dc.type.accesstypeClosed Accessen_US

Files

Collections

Pharmaceutical Sciences and Natural Products - Research Publications